inclusion criteria: * subjects who meet all inclusion criteria will be included. 1. male or non-pregnant female, aged 20 to 60 years old (inclusive). 2. subject who is physically and mentally capable of participating the study and are willing to adhere to study procedures. 3. subject with no clinically significant abnormal findings in medical history, physical examination, vital signs, or clinical laboratory results at the screening visit based on the investigator's judgment. 4. subject with negative test result in sars-cov-2 antibody (igg and igm) rapid test at the screening visit. 5. subject with negative serology test results for human immunodeficiency virus (hiv) antibody, hepatitis b surface antigen, and hepatitis c antibody at the screening visit. 6. subjects' clinical laboratory test results are in the normal range or with abnormal values without clinical significance as judged by the investigator. 7. female subject with childbearing potential must have negative result in urine pregnancy test at the screening visit. 8. female subject with childbearing potential must be willing to implement adequate, highly effective contraceptive measure during the study period. effective birth control includes: 1. intrauterine device plus one barrier method 2. oral, implantable, or injectable contraceptives plus one barrier method; or 3. two barrier methods effective barrier methods are male or female condoms, diaphragms, or spermicides (creams or gels that contain a chemical to kill sperm). women of childbearing potential are those who have not been surgically sterilized or have not been free from menses for ≥ 1 year. 9. male subject who agrees to use an adequate method of contraception during the study period \[e.g., barrier contraceptives (male condom)\]. 10. subject who provides informed consent after receiving a detailed explanation of study procedures.

inclusion criteria: * subjects who meet all inclusion criteria will be included. 1. male or non-pregnant female, aged 20 to 60 years old (inclusive). 2. subject who is physically and mentally capable of participating the study and are willing to adhere to study procedures. 3. subject with no clinically significant abnormal findings in medical history, physical examination, vital signs, or clinical laboratory results at the screening visit based on the investigator's judgment. 4. subject with negative test result in sars-cov-2 antibody (igg and igm) rapid test at the screening visit. 5. subject with negative serology test results for human immunodeficiency virus (hiv) antibody, hepatitis b surface antigen, and hepatitis c antibody at the screening visit. 6. subjects' clinical laboratory test results are in the normal range or with abnormal values without clinical significance as judged by the investigator. 7. female subject with childbearing potential must have negative result in urine pregnancy test at the screening visit. 8. female subject with childbearing potential must be willing to implement adequate, highly effective contraceptive measure during the study period. effective birth control includes: 1. intrauterine device plus one barrier method 2. oral, implantable, or injectable contraceptives plus one barrier method; or 3. two barrier methods effective barrier methods are male or female condoms, diaphragms, or spermicides (creams or gels that contain a chemical to kill sperm). women of childbearing potential are those who have not been surgically sterilized or have not been free from menses for ≥ 1 year. 9. male subject who agrees to use an adequate method of contraception during the study period \[e.g., barrier contraceptives (male condom)\]. 10. subject who provides informed consent after receiving a detailed explanation of study procedures.

inclusion criteria: subjects who meet all inclusion criteria will be included. male or non-pregnant female, aged 20 to 60 years old (inclusive). subject who is physically and mentally capable of participating the study and are willing to adhere to study procedures. subject with no clinically significant abnormal findings in medical history, physical examination, vital signs, or clinical laboratory results at the screening visit based on the investigator's judgment. subject with negative test result in sars-cov-2 antibody (igg and igm) rapid test at the screening visit. subject with negative serology test results for human immunodeficiency virus (hiv) antibody, hepatitis b surface antigen, and hepatitis c antibody at the screening visit. subjects' clinical laboratory test results are in the normal range or with abnormal values without clinical significance as judged by the investigator. female subject with childbearing potential must have negative result in urine pregnancy test at the screening visit. female subject with childbearing potential must be willing to implement adequate, highly effective contraceptive measure during the study period. effective birth control includes: intrauterine device plus one barrier method oral, implantable, or injectable contraceptives plus one barrier method; or two barrier methods effective barrier methods are male or female condoms, diaphragms, or spermicides (creams or gels that contain a chemical to kill sperm). women of childbearing potential are those who have not been surgically sterilized or have not been free from menses for ≥ 1 year. male subject who agrees to use an adequate method of contraception during the study period [e.g., barrier contraceptives (male condom)]. subject who provides informed consent after receiving a detailed explanation of study procedures.

inclusion criteria: subjects who meet all inclusion criteria will be included. male or non-pregnant female, aged 20 to 60 years old (inclusive). subject who is physically and mentally capable of participating the study and are willing to adhere to study procedures. subject with no clinically significant abnormal findings in medical history, physical examination, vital signs, or clinical laboratory results at the screening visit based on the investigator's judgment. subject with negative test result in sars-cov-2 antibody (igg and igm) rapid test at the screening visit. subject with negative serology test results for human immunodeficiency virus (hiv) antibody, hepatitis b surface antigen, and hepatitis c antibody at the screening visit. subjects' clinical laboratory test results are in the normal range or with abnormal values without clinical significance as judged by the investigator. female subject with childbearing potential must have negative result in urine pregnancy test at the screening visit. female subject with childbearing potential must be willing to implement adequate, highly effective contraceptive measure during the study period. effective birth control includes: intrauterine device plus one barrier method oral, implantable, or injectable contraceptives plus one barrier method; or two barrier methods effective barrier methods are male or female condoms, diaphragms, or spermicides (creams or gels that contain a chemical to kill sperm). women of childbearing potential are those who have not been surgically sterilized or have not been free from menses for ≥ 1 year. male subject who agrees to use an adequate method of contraception during the study period [e.g., barrier contraceptives (male condom)]. subject who provides informed consent after receiving a detailed explanation of study procedures.

inclusion criteria: - subjects who meet all inclusion criteria will be included. 1. male or non-pregnant female, aged 20 to 60 years old (inclusive). 2. subject who is physically and mentally capable of participating the study and are willing to adhere to study procedures. 3. subject with no clinically significant abnormal findings in medical history, physical examination, vital signs, or clinical laboratory results at the screening visit based on the investigator's judgment. 4. subject with negative test result in sars-cov-2 antibody (igg and igm) rapid test at the screening visit. 5. subject with negative serology test results for human immunodeficiency virus (hiv) antibody, hepatitis b surface antigen, and hepatitis c antibody at the screening visit. 6. subjects' clinical laboratory test results are in the normal range or with abnormal values without clinical significance as judged by the investigator. 7. female subject with childbearing potential must have negative result in urine pregnancy test at the screening visit. 8. female subject with childbearing potential must be willing to implement adequate, highly effective contraceptive measure during the study period. effective birth control includes: 1. intrauterine device plus one barrier method 2. oral, implantable, or injectable contraceptives plus one barrier method; or 3. two barrier methods effective barrier methods are male or female condoms, diaphragms, or spermicides (creams or gels that contain a chemical to kill sperm). women of childbearing potential are those who have not been surgically sterilized or have not been free from menses for ≥ 1 year. 9. male subject who agrees to use an adequate method of contraception during the study period [e.g., barrier contraceptives (male condom)]. 10. subject who provides informed consent after receiving a detailed explanation of study procedures.

inclusion criteria: - subjects who meet all inclusion criteria will be included. 1. male or non-pregnant female, aged 20 to 60 years old (inclusive). 2. subject who is physically and mentally capable of participating the study and are willing to adhere to study procedures. 3. subject with no clinically significant abnormal findings in medical history, physical examination, vital signs, or clinical laboratory results at the screening visit based on the investigator's judgment. 4. subject with negative test result in sars-cov-2 antibody (igg and igm) rapid test at the screening visit. 5. subject with negative serology test results for human immunodeficiency virus (hiv) antibody, hepatitis b surface antigen, and hepatitis c antibody at the screening visit. 6. subjects' clinical laboratory test results are in the normal range or with abnormal values without clinical significance as judged by the investigator. 7. female subject with childbearing potential must have negative result in urine pregnancy test at the screening visit. 8. female subject with childbearing potential must be willing to implement adequate, highly effective contraceptive measure during the study period. effective birth control includes: 1. intrauterine device plus one barrier method 2. oral, implantable, or injectable contraceptives plus one barrier method; or 3. two barrier methods effective barrier methods are male or female condoms, diaphragms, or spermicides (creams or gels that contain a chemical to kill sperm). women of childbearing potential are those who have not been surgically sterilized or have not been free from menses for ≥ 1 year. 9. male subject who agrees to use an adequate method of contraception during the study period [e.g., barrier contraceptives (male condom)]. 10. subject who provides informed consent after receiving a detailed explanation of study procedures.